Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration
Acta Ophthalmologica, 06/15/2012
Clinical Article
Lala C et al. – Monthly visits and a morphology–driven pro re nata regimen with 3 injections in case of recurrence plus quarterly injections in case of inactive CNV resulted in an average VA gain of 7–9 letters that could be maintained over 3 years.



